A new, small cancer study may give hope to patients with solid tumors in the stomach, esophagus or rectum. The standard ...

Cancer operations that remove whole or parts of an organ can be life-altering. New research suggests that some patients may ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Research on gastrointestinal diseases, especially cancer, has mainly looked at the epithelial cells, which line the surfaces of organs, are important for various functions, and are believed to be the ...

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

Discussion: This study provides a comprehensive overview of research trends and highlights emerging directions, aiming to advance scientific and clinical applications of gut microbiota in ...

The GI Cancers Symposium revealed new therapies for specific cancer subsets and progress in chimeric antigen receptor T-cell therapies for solid tumors. The recent American Society of Clinical ...

In an interview with Targeted Oncology, Chan, who is clinical director at the Gastrointestinal Cancer Center and director for the Program in Carcinoid and Neuroendocrine Tumors at Dana-Farber Cancer ...